Literature DB >> 6125676

Treatment of chancroid by clavulanic acid with amoxycillin in patients with beta-lactamase-positive Haemophilus ducreyi infection.

M V Fast, H Nsanze, L J D'Costa, F A Plummer, P Karasira, I W Maclean, A R Ronald.   

Abstract

Multiresistant strains of Haemophilus ducreyi, the aetiological agent of chancroid, are prevalent in Nairobi, Kenya, where tetracyclines and sulphonamides are no longer very effective in the treatment of chancroid. The following regimens (given three times daily for seven days) were compared in a double-blind randomised trial--amoxycillin 500 mg, amoxycillin 500 mg and clavulanic acid 125 mg, and amoxycillin 500 mg and clavulanic acid 250 mg. 68 of 100 ulcers were culture-positive for H. ducreyi. All strains of H. ducreyi produced beta-lactamase. At day 7 none of the amoxycillin-treated patients had responded clinically or bacteriologically, whereas all but 2 of 56 patients treated with an amoxycillin/clavulanic-acid regimen had responded clinically and H. ducreyi had been eradicated from their ulcers. The combination of amoxycillin-clavulanic acid appears to be very effective for the treatment of chancroid. The results of this study accord with H. ducreyi as the primary pathogen of chancroid.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6125676     DOI: 10.1016/s0140-6736(82)90597-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  8 in total

1.  In vitro activities of U-63366, a spectinomycin analog; roxithromycin (RU 28965), a new macrolide antibiotic; and five quinolone derivatives against Haemophilus ducreyi.

Authors:  M J Sanson-Le Pors; I M Casin; M C Thebault; G Arlet; Y Perol
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

2.  Monoclonal antibodies reactive with all strains of Haemophilus ducreyi.

Authors:  E J Hansen; T A Loftus
Journal:  Infect Immun       Date:  1984-04       Impact factor: 3.441

3.  Susceptibility of Haemophilus ducreyi to ampicillin and sulbactam in vitro.

Authors:  B M Jones; S Hafiz; B I Duerden
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

Review 4.  Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  P A Todd; P Benfield
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

5.  Amoxycillin and clavulanic acid in the treatment of urinary infection.

Authors:  L G Al Roomi; A M Sutton; F Cockburn; T A McAllister
Journal:  Arch Dis Child       Date:  1984-03       Impact factor: 3.791

6.  Three day oral course of Augmentin to treat chancroid.

Authors:  J O Ndinya-Achola; H Nsanze; P Karasira; L Fransen; L J D'Costa; P Piot; A R Ronald
Journal:  Genitourin Med       Date:  1986-06

7.  Treating gonococcal urethritis in men: oral amoxycillin potentiated by clavulanate compared with intramuscular procaine penicillin.

Authors:  A S Latif; J Sithole; S Bvumbe; B Gumbo; M Kawemba; R S Summers
Journal:  Br J Vener Dis       Date:  1984-02

8.  Single-dose ceftriaxone for chancroid.

Authors:  M I Bowmer; H Nsanze; L J D'Costa; J Dylewski; L Fransen; P Piot; A R Ronald
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.